Freshfields is advising Merck on its $10bn acquisition of respiratory-focused pharmaceutical company Verona Pharma, in a ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co.’s $10 billion ...

Fintel reports that on July 10, 2025, Wells Fargo downgraded their outlook for Verona Pharma plc - Depositary Receipt () ...

Merck says it will acquire London-based Verona Pharma for about US$10bil, gaining a promising respiratory treatment as it ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion last year. Keytruda may also face “ price setting ” from the Inflation ...

The effort appears to be paying off – last year Johnson & Johnson turned to Freshfields over its usual choice Cravath for its $13bn acquisition of medical device maker Shockwave Medical, with the team ...